Combinatorial genetic engineering strategy for immune protection of stem cell-derived beta cells by chimeric antigen receptor regulatory T cells
Комбинаторная стратегия генной инженерии для иммунной защиты бета-клеток, полученных из стволовых клеток, с помощью регуляторных Т-клеток с химерным антигенным рецептором
2024-11-01
SCID: 54.1/bkz7xe4e
Discuss with AI
EGFRtchimeric antigen receptor regulatory T cellscombinatorial genetic engineeringgraft immune protectionstem cell-derived beta cells
Figures from the paper
Abstract (AI)
Regenerative medicine is a rapidly expanding field harnessing human pluripotent stem cell (hPSC)-derived cells and tissues to treat many diseases, including type 1 diabetes. However, graft immune protection remains a key challenge. Chimeric antigen receptor (CAR) technology confers new specificities to effector T cells and immunosuppressive regulatory T cells (Tregs). One challenge in CAR design is identifying target molecules unique to the cells of interest. Here, we employ combinatorial genetic engineering to confer CAR-Treg-mediated localized immune protection to stem cell-derived cells. We engineered hPSCs to express truncated epidermal growth factor receptor (EGFRt), a biologically inert and generalizable target for CAR-Treg homing and activation, and generated CAR-Tregs recognizing EGFRt. Strikingly, CAR-Tregs suppressed innate and adaptive immune responses in vitro and prevented EGFRt-hPSC-derived pancreatic beta-like cell (sBC [stem cell-derived beta cell]) graft immune destruction in vivo. Collectively, we provide proof of concept that hPSCs and Tregs can be co-engineered to protect hPSC-derived cells from immune rejection upon transplantation.
Key Findings
1
A combinatorial genetic engineering strategy co-engineered hPSCs and CAR-Tregs to provide localized immune protection for stem cell-derived grafts.
2
CAR-Tregs targeting EGFRt suppressed both innate and adaptive immune responses in vitro.
3
EGFRt-targeted CAR-Tregs prevented immune destruction of EGFRt-expressing hPSC-derived pancreatic beta-like cell grafts in vivo.
4
The study provides proof of concept for protecting hPSC-derived cells from transplantation-related immune rejection through coordinated engineering of graft cells and Tregs.
5
hPSCs were modified to express truncated EGFR (EGFRt), a biologically inert and generalizable target enabling CAR-Treg homing and activation.
Research Object
stem cell-derived pancreatic beta-like cell grafts engineered to express truncated EGFR (EGFRt) and protected by EGFRt-specific CAR-Tregs
Research Subject
CAR-Treg-mediated localized immune protection and prevention of innate and adaptive immune-mediated graft destruction
Publication Details
Publication Date
2024-11-01
Journal
Cell Reports
Publisher
Cell Press
ISSN
2211-1247
Cited by
42
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest